JP5197015B2 - 抗生物質用即効型投薬形 - Google Patents
抗生物質用即効型投薬形 Download PDFInfo
- Publication number
- JP5197015B2 JP5197015B2 JP2007547462A JP2007547462A JP5197015B2 JP 5197015 B2 JP5197015 B2 JP 5197015B2 JP 2007547462 A JP2007547462 A JP 2007547462A JP 2007547462 A JP2007547462 A JP 2007547462A JP 5197015 B2 JP5197015 B2 JP 5197015B2
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- form according
- coating
- antibiotic
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
Description
例 1
下記の組成の押出ペレットを
高速ミキサー中で出発物質を混合し、ついで湿式造粒(wet granulating)し、 湿性粒状物(moist granules)を押出金型0.5×0.5 mmの押出機によって 35℃以下の押出温度で押出ことによって製造する。押出物を適当な球形化機中で球形化し、得られたペレットを流動床乾燥器中で10%以下の残存水分含有量になるまで乾燥させる。乾燥したペレットをスクリーンニング法によって分級し、すべての篩い分けフラクション250〜710 μmを一緒にする。
例1におけると同様に, 下記組成の押出ペレットを製造する:
例1におけると同様に, 押出ペレットを250 mgのクラリスロマイシン 及び表1に示した助剤を用いて製造する。上記方法に従う、900 mlの 緩衝液中で pH 6.8で及び1分あたり150回転でクラリスロマイシンの放出を、同様に表1に示す。 上記値は、カラギーナン NF (Gelcarin GP-911)単独での使用によっても、これとその他の球形化助剤の混合によっても、十分に速く崩壊し、そして有効成分を十分に速く放出するペレットは得られないことをを示す。
例1におけると同様に, 下記組成を有する押出ペレットを製造する:
コーティングされた粒状物 (Coated granules)
例 1 からのペレットの一部を、それぞれ下記組成の水性分散液を用いてコーティングする:
それぞれのコーティングに対する分散液組成
コーティングされたペレットからの放出
例1におけると同様に, 下記組成を有する押出ペレットを製造する:
コーティング用水性分散液の組成
例1におけると同様に, 下記組成を有する押出ペレットを製造する:
水性コーティング分散液の組成
例1におけると同様に, 下記組成を有する押出ペレットを製造する:
水性コーティング懸濁液の組成
例1におけると同様に, 下記組成を有する押出ペレットを製造する:
水性コーティング分散液の組成
Claims (21)
- 水性媒体に難湿潤性又は難溶性である、少なくとも1種の抗生物質、及びカラギーナン及びリン酸三カルシウムの組み合わせ、及び場合により少なくとも1種のショ糖エステルを含有する、多微粒子状医薬投薬形。
- 押出ペレットの形で存在する、請求項1記載の投薬形。
- 前記押出ペレットが球形で存在する、請求項2記載の投薬形。
- ショ糖エステルが10−16のHLBを示す、請求項1〜3のいずれか1つに記載の投薬形。
- ショ糖エステルが13−15のHLBを示す、請求項4記載の投薬形。
- 投薬形の全重量に対して5〜50重量%のカラギーナンを含有する、請求項1〜5のいずれか1つに記載の投薬形。
- リン酸三カルシウムとカラギーナンの重量比が、1:1〜1:10である、請求項1〜6のいずれか1つに記載の投薬形。
- リン酸三カルシウムが粒子サイズ<50μmの、微分散された粉末として存在する、請求項1〜7のいずれか1つに記載の投薬形。
- ショ糖エステルが投薬形の全重量に対して1−10重量%の量で存在する、請求項1〜8のいずれか1つに記載の投薬形。
- ペニシリン類,セファロスポリン類及びマクロライド類より成る群から選ばれた少なくとも1種の抗生物質を含有する、請求項1〜9のいずれか1つに記載の投薬形。
- 抗生物質がアモキシリン,クラリスロマイシン,アズスロマイシン(一又は二水和物)又はセフィキシム,セフポドキシム及び(又は)セフポドキシムプロキセチルである、請求項1〜10のいずれか1つに記載の投薬形。
- 投薬形が、耐胃液性及び(又は)耐唾液性のフレーバーニュートラルなコーティング(flavour−neutral coating)を有する、請求項1〜11のいずれか1つに記載の投薬形。
- 粒子が<800μmの大きさを有する、請求項1〜12のいずれか1つに記載の投薬形。
- あらゆるコーティングが溶解された後のpH値6−7で投薬形が高い溶出速度を示す、請求項1〜13のいずれか1つに記載の投薬形。
- 抗生物質が、pH値6−7で、30分以内に少なくとも85%の量で放出される、請求項14記載の投薬形。
- 投薬形がアモキシリンを含有し、そしてフレーバーニュートラルなコーティングを有する、請求項1〜15のいずれか1つに記載の投薬形。
- 投薬形がクラリスロマイシンを含有し、そしてフレーバーニュートラルなコーティングを有する、請求項1〜16のいずれか1つに記載の投薬形。
- 出発物質を混合し,粒状化し,押出し、細分化し,球形化し,場合により分級し、ついで場合により耐唾液性及び(又は)耐胃液性及び(又は)フレーバーニュートラルなコーティングを付与する、請求項1〜17のいずれか1つに記載の投薬形の製造方法。
- 出発混合物が湿式粒状化される、請求項18記載の方法。
- 少なくとも1個の単回投与用可動バリヤ装置(mobile barrier device)を有する飲用ストロー中に配置された、請求項1〜17のいずれか1つに記載の投薬形を包含する投薬システム。
- 請求項20記載の投薬システム及びpH≦6の生理学的に許容し得る液体を有するキット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004063409.2 | 2004-12-23 | ||
DE102004063409 | 2004-12-23 | ||
DE102005042875A DE102005042875A1 (de) | 2004-12-23 | 2005-09-08 | Schnell freisetzende Darreichungsformen für Antibiotika |
DE102005042875.4 | 2005-09-08 | ||
PCT/EP2005/056795 WO2006069920A1 (de) | 2004-12-23 | 2005-12-14 | Schnell freisetzende darreichungsformen für antibiotika |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008525367A JP2008525367A (ja) | 2008-07-17 |
JP5197015B2 true JP5197015B2 (ja) | 2013-05-15 |
Family
ID=36168441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007547462A Expired - Fee Related JP5197015B2 (ja) | 2004-12-23 | 2005-12-14 | 抗生物質用即効型投薬形 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8361506B2 (ja) |
EP (1) | EP1830849B1 (ja) |
JP (1) | JP5197015B2 (ja) |
CN (1) | CN101123961B (ja) |
AT (1) | ATE447951T1 (ja) |
DE (2) | DE102005042875A1 (ja) |
ES (1) | ES2336588T3 (ja) |
HK (1) | HK1112402A1 (ja) |
IL (1) | IL184009A (ja) |
PL (1) | PL1830849T3 (ja) |
WO (1) | WO2006069920A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006059510A1 (de) | 2006-12-14 | 2008-06-19 | Grünenthal GmbH | Beschichtete Pellets |
EP2459264B1 (en) | 2009-07-29 | 2013-12-25 | C.R. Bard Inc. | Catheter having improved drainage |
US9821139B2 (en) * | 2009-08-13 | 2017-11-21 | C. R. Bard, Inc. | Catheter having internal hydrating fluid storage and/or catheter package using the same and method of making and/or using the same |
JP2013515572A (ja) | 2009-12-23 | 2013-05-09 | シー・アール・バード・インコーポレーテッド | 水和/ヒドロゲルスリーブを用いたカテーテルアセンブリ/パッケージならびにその作製および使用方法 |
WO2011109393A1 (en) | 2010-03-04 | 2011-09-09 | C.R. Bard, Inc. | Catheter assembly/package utilizing a hydrating/hydrogel sleeve and a foil outer layer and method of making and using the same |
US8998882B2 (en) | 2013-03-13 | 2015-04-07 | C. R. Bard, Inc. | Enhanced pre-wetted intermittent catheter with lubricious coating |
US9980916B2 (en) | 2013-03-15 | 2018-05-29 | Patheon Softgels, Inc. | Non-gelatin enteric soft capsules |
CN106309371B (zh) * | 2015-06-30 | 2020-07-03 | 北京福元医药股份有限公司 | 一种头孢克肟纳米分散体及其制备方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3542972A1 (de) * | 1985-12-05 | 1987-06-11 | Merck Patent Gmbh | Pharmakadepot |
US5356625A (en) * | 1986-08-28 | 1994-10-18 | Enzacor Properties Limited | Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals |
JPH0629173B2 (ja) * | 1986-11-20 | 1994-04-20 | 花王株式会社 | 顆粒剤 |
JP2547995B2 (ja) * | 1987-01-26 | 1996-10-30 | 昭和電工株式会社 | 反すう動物用粒剤及びその製造法 |
ATE123237T1 (de) * | 1990-08-24 | 1995-06-15 | Spirig Ag | Verfahren zur herstellung von pellets. |
US5350584A (en) * | 1992-06-26 | 1994-09-27 | Merck & Co., Inc. | Spheronization process using charged resins |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
WO1998056826A1 (en) * | 1997-06-12 | 1998-12-17 | Fmc Corporation | Ultra-fine microcrystalline cellulose compositions and process for their manufacture |
US6531152B1 (en) * | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
US6159504A (en) * | 1999-01-11 | 2000-12-12 | Kitii Corporation, Ltd. | Core substance-containing calcium microparticles and methods for producing the same |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
US20020076437A1 (en) * | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
DE10029201A1 (de) * | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
US7527807B2 (en) * | 2000-06-21 | 2009-05-05 | Cubist Pharmaceuticals, Inc. | Compositions and methods for increasing the oral absorption of antimicrobials |
CA2448864C (en) * | 2001-06-22 | 2008-04-22 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
JP3866540B2 (ja) * | 2001-07-06 | 2007-01-10 | 株式会社東芝 | 窒化物半導体素子およびその製造方法 |
FR2834212B1 (fr) * | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
BR0306717A (pt) * | 2002-01-03 | 2004-12-28 | Smithkline Beecham Corp | Formas de dosagem farmacêutica e método para a produção das mesmas |
DE10228175A1 (de) * | 2002-03-27 | 2003-10-09 | Gruenenthal Gmbh | Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen |
DE10228171A1 (de) * | 2002-06-24 | 2004-01-22 | Grünenthal GmbH | Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen |
DE10228179A1 (de) * | 2002-06-24 | 2004-01-22 | Grünenthal GmbH | Darreichungsform zur oralen Verabreichung von Wirkstoffen, Vitaminen und/oder Nährstoffen |
-
2005
- 2005-09-08 DE DE102005042875A patent/DE102005042875A1/de not_active Withdrawn
- 2005-12-14 EP EP05850456A patent/EP1830849B1/de not_active Not-in-force
- 2005-12-14 AT AT05850456T patent/ATE447951T1/de active
- 2005-12-14 ES ES05850456T patent/ES2336588T3/es active Active
- 2005-12-14 PL PL05850456T patent/PL1830849T3/pl unknown
- 2005-12-14 WO PCT/EP2005/056795 patent/WO2006069920A1/de active Application Filing
- 2005-12-14 JP JP2007547462A patent/JP5197015B2/ja not_active Expired - Fee Related
- 2005-12-14 DE DE502005008510T patent/DE502005008510D1/de active Active
- 2005-12-14 CN CN2005800485251A patent/CN101123961B/zh not_active Expired - Fee Related
-
2007
- 2007-06-18 IL IL184009A patent/IL184009A/en not_active IP Right Cessation
- 2007-06-22 US US11/767,228 patent/US8361506B2/en active Active
-
2008
- 2008-02-21 HK HK08101926.9A patent/HK1112402A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE102005042875A1 (de) | 2006-09-21 |
DE502005008510D1 (de) | 2009-12-24 |
IL184009A0 (en) | 2007-10-31 |
CN101123961A (zh) | 2008-02-13 |
HK1112402A1 (en) | 2008-09-05 |
US8361506B2 (en) | 2013-01-29 |
ES2336588T3 (es) | 2010-04-14 |
JP2008525367A (ja) | 2008-07-17 |
PL1830849T3 (pl) | 2010-04-30 |
IL184009A (en) | 2010-11-30 |
WO2006069920A1 (de) | 2006-07-06 |
US20080050446A1 (en) | 2008-02-28 |
ATE447951T1 (de) | 2009-11-15 |
EP1830849A1 (de) | 2007-09-12 |
CN101123961B (zh) | 2012-10-03 |
EP1830849B1 (de) | 2009-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5197015B2 (ja) | 抗生物質用即効型投薬形 | |
AU760006B2 (en) | Method for making granules with masked taste and instant release of the active particle | |
AU2001255509B2 (en) | Taste masking coating composition | |
RU2527766C2 (ru) | Таблетки и гранулированные порошки, содержащие 6-фтор-3-гидрокси-2-пиразинкарбоксамид | |
KR101141508B1 (ko) | 판토프라졸 복합 미립자 제형 | |
WO2011077451A2 (en) | Controlled release pharmaceutical composition | |
JPH05500674A (ja) | 医薬製剤 | |
US20070036860A1 (en) | Treatment of allergic conditions | |
KR20020031382A (ko) | 맛을 차폐시킨 약제학적 액체 제제 | |
US20100183730A1 (en) | High dose composition of ursodeoxycholic acid | |
CZ20011845A3 (cs) | Farmaceutické přípravky obsahující cefuroximaxetil | |
JP2004507487A (ja) | 腸疾患治療薬 | |
KR101343283B1 (ko) | 수 현탁성을 향상시킨 세립제 | |
JP2014516961A (ja) | 多粒子医薬組成物 | |
KR101680925B1 (ko) | 불쾌미 마스킹 입자 및 이것을 함유하는 경구제제 | |
KR20180120268A (ko) | 시스테아민 또는 이의 염을 포함하는 서방형 약학적 조성물 | |
WO2014104929A1 (ru) | Фармацевтическая композиция для лечения вич-инфекции | |
KR102246658B1 (ko) | 탐수로신 염산염 함유 서방성 과립을 포함하는 경구용 약제학적 제제 | |
JP2005060310A (ja) | 不快な味をマスキングする経口投与用製剤 | |
WO2022072099A1 (en) | Immediate release dosage forms, methods of making and using | |
EA043575B1 (ru) | Фармацевтическая композиция для перорального приема с контролируемой скоростью растворения, содержащая пеллеты с замедленным высвобождением, содержащие тамсулозина гидрохлорид | |
WO2008015686A1 (en) | Stable multiparticulate formulations of didanosine | |
CZ235799A3 (cs) | Farmaceutická dávkovači forma s rychlým uvolňováním a maskující chuť a způsob její výroby |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081205 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100518 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120518 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120525 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120815 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121130 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130122 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130205 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160215 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |